Cholangiocarcinomas Terminated Phase 1 / 2 Trials for Sorafenib (DB00398)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00955721A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract CancerTreatment